bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.09.16.676660

Infants who develop BPD have an airway endotype defined by vimentin expression and ciliary loss

Abstract

RationaleBronchopulmonary Dysplasia (BPD) results from abnormal lung development after preterm birth, with structural deficits at every respiratory tree level. BPD with lower airway disease is emerging as a clinically significant phenotype with increased mortality, and there is a significant knowledge gap in the molecular mechanisms whereby preterm birth disrupts normal airway development. ObjectivesTo develop a human model of lower airway disease after preterm birth and to characterize a molecular endotype of evolving BPD (eBPD) at baseline and in response to injury. MethodsWe used a combination of an ex vivo organotypic Airway Epithelial Cell (AEC models) and well-characterized pathologic and transcriptomic patient samples for quantitative immunohistochemistry and RNA sequencing analyses. Measurements and Main ResultsCompared to AECs from healthy patients, eBPD- derived AECs have a molecular endotype of reduced proliferation, impaired differentiation to ciliated epithelium, and an expanded vimentin-positive population with a transcriptional shift toward stromal cell-associated genes. With hyperoxia exposure, eBPD-derived AECs exhibited a pronounced vimentin response ex vivo, which parallels the increased vimentin expression of airway cells observed in lung tissue from human infants with BPD. ConclusionsIn this organotypic model of neonatal airway differentiation, we find that infants with eBPD have impaired differentiation, increased expression of vimentin, and concomitant loss of cilia, with an exaggerated increase in vimentin expression after hyperoxia injury, findings that mimic the effects of prematurity in airway cells in human patients. These data provide a foundation for future mechanistic studies interrogating the role of intermediate filaments in epithelial differentiation and repair.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eldredge, L. C., Han, Y., Deutsch, G. H., Sucre, J. M. S., Shirazi, S. P., Stefani, C., Pribitzer, S., Reeves, S. R., Rich, L. M., Vanderwall, E. R., Ziegler, S. F., Debley, J. S.. 2025-09-18. Infants who develop BPD have an airway endotype defined by vimentin expression and ciliary loss. https://doi.org/10.1101/2025.09.16.676660

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

High-content screening identifies FDA-approved activators of mitophagy

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

cell biology↗

A LOV-domain photoreceptor mediates phototaxis in brown algae

Phototaxis enables motile cells to navigate light environments and plays a critical role in survival and reproduction across diverse eukaryotic lineages. This ability has evolved independently through distinct photoreceptor systems. Yet, the molecular mechanisms underlying phototaxis remain poorly understood in many major eukaryotic lineages, including stramenopiles. Here, combining functional genetics, cell biology and evolutionary analyses, we identify Helmchrome (HELM), a LOV-domain protein required for phototaxis in the brown alga Ectocarpus. HELM localizes to the posterior flagellum and is responsible for the characteristic flavin-associated fluorescence of brown algal gametes. Loss of HELM abolishes phototactic accumulation and directional orientation without affecting basal motility or fertilization, demonstrating its specific requirement for light-directed movement. Phylogenetic analyses reveal that HELM-like proteins are distributed across diverse stramenopile lineages and that their domain architecture evolved through repeated duplication of an ancestral RGS-LOV module. Our findings identify HELM as a key component of the light-sensing machinery in brown algae, provide a molecular explanation for the long-standing observation of flagellar flavin fluorescence, and reveal a distinct phototaxis system that expands the known diversity of eukaryotic light-sensing mechanisms.

cell biology↗

A distinct chondrogenic progenitor population from human umbilical cord derived mesenchymal stromal cells for osteoarthritis therapy

Stem cell-based cartilage regeneration remains constrained by functional heterogeneity and phenotypic drift in conventional cell sources, compromising durable structural repair. Human umbilical cord-derived mesenchymal stromal cells (UC-MSCs) represent an accessible, off-the-shelf cell source; however, their broad clinical utility is hampered by cellular heterogeneity, leaving the key chondrogenic subpopulation responsible for cartilage repair unresolved. By integrating single-cell transcriptomics with functional assays, we identified and prospectively isolated a distinct, highly expandable subpopulation of skeletal stem cell-like progenitors (U-CPCs) from the human umbilical cord, establishing an extra-skeletal cell source uniquely primed for joint restoration. Single-cell transcriptomics reveal their inherent regulatory landscape, uncovering a distinct transcriptional state uniquely primed for chondrogenesis. In comparison with conventional stem cells and other tissue-derived SSC-like populations (from umbilical cord, bone marrow, adipose tissue, and dental pulp), U-CPCs exhibit a markedly enhanced chondrogenic capacity. In both a mouse cartilage injury model and a rat osteoarthritis model, the administration of U-CPCs effectively mitigates joint degeneration and drives the restoration of a structurally sound, hyaline-like matrix. Mechanistically, U-CPCs secrete extracellular vesicles enriched with microRNA Let-7a-5p, which specifically modulates DUSP7/MAPK/ERK signaling in recipient chondrocytes, thereby restoring extracellular matrix homeostasis and promoting cartilage repair. By characterizing these specialized extra-skeletal progenitors and elucidating both their intrinsic chondrogenic priming and paracrine regulation of host tissue, this study establishes U-CPCs as a robust, lineage-restricted cellular source for osteoarthritis therapy.

cell biology↗